Literature DB >> 17900571

Characterization of proliferating cell nuclear antigen (PCNA) isoforms in normal and cancer cells: there is no cancer-associated form of PCNA.

Stanislav N Naryzhny1, Hoyun Lee.   

Abstract

In order to clarify the status of PCNA in normal and transformed cells, we performed analysis of this protein by 2D-PAGE, Western blot and mass spectrometry. All the cell lines examined contained the major PCNA form (pI 4.57/30kDa), that is not post-translationally modified. In addition to the major form, two minor isoforms (pI 4.52/30kDa and pI 4.62/30kDa) were also detected in all the cell lines examined. However, the level of PCNA in cancer cells is 5-6 folds higher than those in primary and most of the immortalized cells. Taken together, the significant difference in PCNA status between cancer and normal cells is not at the post-translational modifications but in the overall levels of PCNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900571     DOI: 10.1016/j.febslet.2007.09.022

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.

Authors:  Zongqing Tan; Matthew Wortman; Kelsey L Dillehay; William L Seibel; Chris R Evelyn; Shanna J Smith; Linda H Malkas; Yi Zheng; Shan Lu; Zhongyun Dong
Journal:  Mol Pharmacol       Date:  2012-03-07       Impact factor: 4.436

2.  Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44.

Authors:  Benyamin Rosental; Michael Brusilovsky; Uzi Hadad; Dafna Oz; Michael Y Appel; Fabian Afergan; Rami Yossef; Lior Ann Rosenberg; Amir Aharoni; Adelheid Cerwenka; Kerry S Campbell; Alex Braiman; Angel Porgador
Journal:  J Immunol       Date:  2011-10-21       Impact factor: 5.422

3.  Renal carcinogenesis after uninephrectomy.

Authors:  Yi Sui; Hai-Lu Zhao; Heung Man Lee; Jing Guan; Lan He; Fernand Mm Lai; Peter Cy Tong; Juliana Cn Chan
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

4.  Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44.

Authors:  Nathan C Horton; Stephen O Mathew; Porunelloor A Mathew
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

5.  The chemopotential effect of Annona muricata leaves against azoxymethane-induced colonic aberrant crypt foci in rats and the apoptotic effect of Acetogenin Annomuricin E in HT-29 cells: a bioassay-guided approach.

Authors:  Soheil Zorofchian Moghadamtousi; Elham Rouhollahi; Hamed Karimian; Mehran Fadaeinasab; Mohammad Firoozinia; Mahmood Ameen Abdulla; Habsah Abdul Kadir
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  PCNA appears in two populations of slow and fast diffusion with a constant ratio throughout S-phase in replicating mammalian cells.

Authors:  Patrick J M Zessin; Anje Sporbert; Mike Heilemann
Journal:  Sci Rep       Date:  2016-01-13       Impact factor: 4.379

7.  A proteomic analysis of acute leukemia cells treated with 9-hydroxyoctadecadienoic acid.

Authors:  Zhen Li; Bohong Chen; Ping Wang; Xin Li; Gaotai Cai; Wei Wei; Wenqi Dong
Journal:  Lipids Health Dis       Date:  2016-11-10       Impact factor: 3.876

Review 8.  Towards the Full Realization of 2DE Power.

Authors:  Stanislav Naryzhny
Journal:  Proteomes       Date:  2016-11-15

9.  Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes.

Authors:  Karin Zins; Gerwin Heller; Mathias Mayerhofer; Martin Schreiber; Dietmar Abraham
Journal:  Oncotarget       Date:  2018-05-01

10.  The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats.

Authors:  Elham Rouhollahi; Soheil Zorofchian Moghadamtousi; Nawal Al-Henhena; Thubasni Kunasegaran; Mohadeseh Hasanpourghadi; Chung Yeng Looi; Sri Nurestri Abd Malek; Khalijah Awang; Mahmood Ameen Abdulla; Zahurin Mohamed
Journal:  Drug Des Devel Ther       Date:  2015-07-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.